Accessibility Menu
Valneva Se logo

Valneva Se(NASDAQ) VALN

Market Cap$453.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-83%
5 Year-83%
1 Year-37%
1 Month-9%
$4.99
+4.39%
+0.21Today
Valneva Se last closing stock price
MetricPriceDate
Last closeUSD 4.782026-07-24
Valneva Se stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.4%USD 5.002026-07-17
1 month-8.6%USD 5.232026-06-24
3 month-13.09%USD 5.502026-04-24
Year to date-45.8%USD 8.822025-12-31
1 year-37%USD 7.592025-07-24
3 year-67.52%USD 14.722023-07-25
5 year-82.65%USD 27.552021-07-23
Since inception-83.14%USD 28.352021-05-06

Valneva Se Financials at a Glance

Market Cap

$453.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€156.33M

Net Income (TTM)

-€138.03M

EPS (TTM)

-$1.87

P/E Ratio

-2.55

Dividend

$0.00

Beta (Volatility)

0.99 (Low)

Price

$4.99

Volume

4,481

Open

$4.97

Previous Close

$4.96

Daily Range

$4.90 - $5.06

52-Week Range

$4.75 - $12.25

Estimated Earnings Date

Aug 11, 2026

VALN News

GettyImages-1341058702(1)

Is This New Data on Valneva's Less-Effective Booster Concerning?

Keith SpeightsDec 18, 2021
GettyImages-1356307353

2 Stocks That Could Soar With the Emergence of the Omicron Variant

Keith SpeightsDec 12, 2021
Vaccine GettyImages-1298099807

These 2 Nasdaq Biotechs Are Making Huge Premarket Moves Monday

Dan CaplingerOct 18, 2021

VALN: Motley Fool Moneyball Superscore

51

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Valneva Se

Valneva SE is a specialty vaccine company focused on developing vaccines for infectious diseases with significant unmet needs. With its strong foundation in proprietary technologies and strategic collaborations, Valneva aims to swiftly address emerging health threats. The company is guided by a management team with extensive expertise in vaccine development and commercialization, driving its growth strategy centered on high-potential markets and innovative vaccines.

Products and Services

Prophylactic vaccines for infectious diseases such as Lyme disease and chikungunya.

Advanced clinical programs for emerging health threats.

Strategic partnerships with global health organizations and biotech firms.

What Makes Valneva SE Special

Valneva SE distinguishes itself with its focused approach to vaccine development for diseases with unmet needs, leveraging proprietary technologies and strategic partnerships. Its capability to quickly address health threats and expand its R&D pipeline through collaborations enhances its market position.

Five Things You Need to Know

Valneva SE specializes in prophylactic vaccines targeting unmet medical needs.

The company utilizes proprietary technologies and strategic collaborations to enhance development and market access.

Valneva has ongoing clinical programs for vaccines against Lyme disease and chikungunya.

The management team has a proven track record in vaccine development and navigating regulatory landscapes.

Strategic alliances provide financial support and market access, promoting innovation and expansion.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

674

CEO

Thomas Lingelbach, PhD

Website

www.valneva.com

Headquarters

Saint-Herblain, GE 44800, FR

VALN Financials

Key Financial Metrics (TTM)

Gross Margin

29.46%

Operating Margin

-68.81%

Net Income Margin

-88.30%

Return on Equity

-106.22%

Return on Capital

-26.05%

Return on Assets

-37.10%

Earnings Yield

-39.22%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$453.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

94.82M

Volume

4.48K

Avg. Volume

31.25K

Financials (TTM)

Gross Profit

€46.05M

Operating Income

-€99.37M

EBITDA

-€77.60M

Operating Cash Flow

-€67.49M

Capital Expenditure

-€3.42M

Free Cash Flow

-€70.92M

Cash & ST Invst.

€105.37M

Total Debt

€209.72M

Valneva Se Performance Analysis

Valneva Se annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 379,720,174-7.7%
20232023-12-31EUR 166,181,523-56.2%
20242024-12-31EUR 183,432,03710.4%
20252025-12-31EUR 197,116,2967.5%
Valneva Se sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-1.8%
Q32025-09-30-39.1%
Q42025-12-3162.2%
Q12026-03-31-35.2%
Valneva Se annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR -2.6146.7%
20232023-12-31EUR -1.58-39.3%
20242024-12-31EUR -0.18-88.5%
20252025-12-31EUR -1.55750.4%
Valneva Se sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-25.5%
Q32025-09-30-245.3%
Q42025-12-31-11.5%
Q12026-03-3134.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

€30.90M

-37.2%

Gross Profit

€4.72M

-82.0%

Gross Margin

15.28%

N/A

Market Cap

$453.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$672.49K

N/A

Employees

674

N/A

Net Income

-€32.07M

-247.4%

EBITDA

-€19.46M

-751.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

€105.37M

-31.1%

Total Debt

€209.72M

-0.7%

Accounts Receivable

€10.14M

-69.7%

Inventory

€50.64M

-17.9%

Long Term Debt

€188.69M

-0.0%

Short Term Debt

€21.01M

-6.2%

Return on Assets

-37.10%

N/A

Return on Invested Capital

-38.72%

N/A

Free Cash Flow

-€565.00K

+94.1%

Operating Cash Flow

-€313.00K

+96.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
DNAGinkgo Bioworks Holdings, Inc.
$7.45+1.29%
ARVNArvinas, Inc.
$8.22+2.37%
REPLReplimune Group, Inc.
$8.63-11.03%
GERNGeron Corporation
$1.48+4.23%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$91.67-0.01%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.28+0.02%
AALAmerican Airlines Group
$14.95+0.03%

Questions About VALN

What is the current price of Valneva Se?

Valneva Se is trading at $4.96 per share.

What is the 52-week range for Valneva Se?

Over the past 52 weeks, Valneva Se has traded between $4.75 and $12.25.

How much debt does Valneva Se have?

As of the most recent reporting period, Valneva Se reported total debt of €241.39M.

How much cash does Valneva Se have on hand?

Valneva Se reported €121.29M in cash and cash equivalents in its most recent financial results.

What is Valneva Se’s dividend yield?

Valneva Se does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services